Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Warnings from experts indicate Ozempic and similar drugs such as Wegovy and Mounjaro can cause the critical medical condition ...

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

To support the development of next-gen therapies, including GLP-1 drugs for diabetes and obesity.

Researchers looked at the nine people who had vision problems while using the drugs and is one of several that have ...

Obesity is an epidemic in the United States, but more people are shedding pounds with the help of weight loss drugs.

Researchers looked at the nine people who had vision problems while using the drugs and is one of several that have ...

A study finds GLP-1 weight-loss drugs may pose vision risks, revealing an unexpected medical irony. A paradoxical insight: ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

Reports link GLP-1 medications like Ozempic and Mounjaro to vision loss, prompting concerns over their safety.

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The ...